Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
C Strange, V Walker, M DePietro, J Tong… - … Journal of Chronic …, 2019 - Taylor & Francis
Background: This study compared real-world patient-reported outcomes (PROs) measured
by the Clinical COPD Questionnaire (CCQ), the London Chest Activities of Daily Living …
by the Clinical COPD Questionnaire (CCQ), the London Chest Activities of Daily Living …
Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
R Buhl, CP Criée, P Kardos… - … Journal of Chronic …, 2018 - Taylor & Francis
Background No observational studies have evaluated the “real-world” effectiveness of dual
bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic …
bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic …
[HTML][HTML] A retrospective claims analysis of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in patients with chronic obstructive …
C Strange, V Walker, J Tong, J Kurlander… - … Diseases: Journal of …, 2019 - ncbi.nlm.nih.gov
Introduction: Patients with chronic obstructive pulmonary disease (COPD) increasingly
receive combination bronchodilator therapies. Real world evidence for the benefits of …
receive combination bronchodilator therapies. Real world evidence for the benefits of …
[HTML][HTML] The role of fixed-dose dual bronchodilator therapy in treating COPD
A Anzueto, M Miravitlles - The American journal of medicine, 2018 - Elsevier
The incidence of chronic obstructive pulmonary disease (COPD) is rising in the United
States, and the disease represents a significant source of morbidity and mortality. Primary …
States, and the disease represents a significant source of morbidity and mortality. Primary …
Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world'study
CF Vogelmeier, H Worth, R Buhl, CP Criée… - Respiratory …, 2022 - Springer
Introduction Chronic obstructive pulmonary disease (COPD) guidelines recommend
reserving triple therapy of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and …
reserving triple therapy of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and …
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial
CF Vogelmeier, EM Kerwin… - Therapeutic …, 2020 - journals.sagepub.com
Rationale: Symptom relief is a key treatment goal in patients with chronic obstructive
pulmonary disease (COPD). However, there are limited data available on the response to …
pulmonary disease (COPD). However, there are limited data available on the response to …
Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 …
Background Which patients should receive dual therapy as initial treatment for chronic
obstructive pulmonary disease (COPD) is only loosely defined. We evaluated if a lower …
obstructive pulmonary disease (COPD) is only loosely defined. We evaluated if a lower …
Comparative real-world effectiveness of triple therapy versus dual bronchodilation on lung function decline in frequently exacerbating patients with COPD
J Voorham, M Kerkhof, G Georges, S Vezzoli… - B45. COPD …, 2019 - atsjournals.org
Background. Randomized controlled clinical trials (RCTs) have shown that patients on triple
therapy (ICS+ LAMA+ LABA or TT) have a higher expiratory volume in 1 second (FEV1) after …
therapy (ICS+ LAMA+ LABA or TT) have a higher expiratory volume in 1 second (FEV1) after …
Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis
EL Huisman, SM Cockle, AS Ismaila… - … Journal of Chronic …, 2015 - Taylor & Francis
Background Several new fixed-dose combination bronchodilators have been recently
launched, and assessing their efficacy relative to each other, and with open dual …
launched, and assessing their efficacy relative to each other, and with open dual …
Future concepts in bronchodilation for COPD: dual-versus monotherapy
D Singh, JF Donohue, IH Boucot… - European …, 2021 - Eur Respiratory Soc
Most patients with COPD are recommended to initiate maintenance therapy with a single
long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2 …
long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2 …